All In Biotech

NDA 022081 · Gilead

Letairis

Ambrisentan · Oral · Endothelin Receptor Antagonist

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jun 15, 2007

Approved uses

3

Original approval plus efficacy supplements

Registered trials

66

23 Phase 3, 5 recruiting

FAERS reports

124,904

80,905 serious, 17,062 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY Letairis is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals [see Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ] . Therefore, for females of reproductive potential, exclude pregnancy before the initiation of treatment with Letairis. Advise use of effective contraception before initiation, during treatment, and for one month after treatment with Letairis [see Dosage and Administration (2.2) Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ]. When pregnancy is detected, discontinue Letairis as soon as possible ( 5.1 ). WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Based on animal data Letairis may cause fetal harm if...

What it is approved for

From the label in effect Jun 22, 2026.

Letairis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability [see Clinical Studies (14.2) ]. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).

Mechanism: Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ET A and ET B , mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ET A are vasoconstriction and cell proliferation, while the predominant actions of ET B are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 2015 Supplement 33 · Efficacy OrphanLetterLabel
  • Feb 15, 2012 Supplement 14 · Efficacy LetterLabel
  • Jun 15, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelREMSLetter
2 products under this application
  • LETAIRIS · AMBRISENTAN 5MG · TABLET, ORAL · Prescription · TE AB
  • LETAIRIS · AMBRISENTAN 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ambrisentan" as an intervention, any sponsor and status, largest first.

All 66 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea19,248
  • death11,390
  • headache10,875
  • pneumonia7,286
  • diarrhoea7,182
  • fatigue6,670
  • dizziness6,625
  • nausea6,611
  • fluid retention5,493
  • malaise5,357
  • cough4,658
  • oedema peripheral4,223

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200767
2008595
2009883
20101,542
20112,831
20124,290
20139,021
201427,939
20159,463
20169,456
20179,414
20189,831
20198,079
20204,916
20214,551
20225,429
20235,506
20245,134
20253,775
20262,182

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Letairis (Ambrisentan)

2024 spending

$82.7M

Beneficiaries

1,309

6,082 claims

Per beneficiary

$63,163

$408.89 per unit

View as table
YearSpending
2020$165,369,501
2021$125,766,283
2022$100,977,936
2023$88,566,586
2024$82,679,794

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 80 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.